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Summaryt\^
Atrial Fibri l lation
Atr ia l  f ibr i l la t ion is ,  a f ter  premature beats f rom the at r ia  and ventr ic les,  the most  f requent-
ly  encountered arrhythmia in  ambulatory pat ients.The prevalence of  at r ia l  f ibr i l la t ion was
est imated to be 0.8% in the Nether lands in  the year  2000.  Fur thermore,  at r ia l  f ibr i l la t ion
is  a common compl icat ion of  coronary ar tery bypass graf t ing.The arrhythmia has been
reported in up to 50o/o f patients during the first days after the operation.
lmpulses f rom foc i ,  located in  the pulmonary veins or  at  other  at r ia l  s i tes,  can in i t ia te
atr ia l  f ibr i l la t ion i f  non homogenei ty  of  conduct ion and atr ia l  ref ractor iness i  suf f ic ient
to cause re-entry .  Atr ia l  e lect r ica l  remodel l ing occurs wi th in a few hours af ter  the onset
of  at r ia l  f ibr i l la t ion and perpetuates the arrhythmia.  Dur ing at r ia l  f ibr i l la t ion the at r ium
is act ivated by mul t ip le randomly re-enter ing funct ional  c i rcu i ts .  l t  is  f requent ly  associ -
ated with a rapid, irregular ventricular response. Paroxysmal atrial, one of the patterns of
the arrhythmia,  is  character ized by recurrent  episodes of  at r ia l  f ibr i l la t ion,  which of ten
terminate spontaneously.  Such an at tack of  at r ia l  f ibr i l la t ion f requent ly  resul ts  in  hemody-
namic impairment  and is  accompanied by symptoms such as palp i ta t ions,  d izz iness,  chest
pain,  perspi rat ion,  co ldness and anxiety.  ln  ambulatory pat ients,  paroxysmal  at r ia l  f ibr i l la-
t ion even appears to have a negat ive impact  on qual i ty  of  l i fe .
Af ter  a pat ient  has exper ienced one or  more episodes of  at r ia l  f ibr i l la t ion chronic
t reatment  wi th ant iarrhythmic drugs is  of ten star ted e i ther  to mainta in s inus rhythm or
to reduce ventr icu lar  ate.  In  pat ients who become aware of  the arrhythmia immediate ly
or  shor t ly  af ter  i ts  sudden onset ,  se l f  adminis t rat ion of  an ant iarrhythmic drug to restore
s inus rhythm in the outc l in ic  s i tuat ion,  i .e .  episodic t reatment ,  might  be a usefu l  a l terna-
t ive to chronic t reatment .  Such episodic t reatment  might  have advantages compared to a
chronic t reatment  wi th ant iarrhythmics.  Pat ient  non compl iance for  ant iarrhythmic drugs,
s ide ef fects that  necessi tate a change in dosage or  d iscont inuat ion of  the medicat ion and
the incomplete suppression of  at tacks of  at r ia l  f ibr i l la t ion are recognized d isadvantages.
Fur thermore,  episodic t reatment  impl ies an ear ly  in tervent ion which seems at t ract ive
s ince i t  might  g ive an ear ly  re l ie f  of  symptoms and might  prevent  the occurrence of
e lect r ica l  remodel l ing which promotes i ts  perpetuat ion.  No proper ly  designed,  contro l -
led,  prospect ive studies on episodic t reatment  of  paroxysmal  at r ia l  f ibr i l la t ion are found
in l i terature.
Atr ia l  f ibr i l la t ion of ten occurs fo l lowing coronary ar tery bypass graf t ing dur ing the f i rs t
days af ter  the procedure.  Al though the arrhythmia is  in  general  not  l i fe- threatening and
of ten sel f - l imi t ing,  i t  can have hemodynamic consequences,  increases the inc idence of
per ioperat ive st roke and my lead to in to lerable symptoms requi r ing addi t ional  drug
therapy or  e lect r ica l  card iovers ion.  The development  of  at r ia l  f ibr i l la t ion has been as-
sociated wi th an increased length of  hospi ta l  s tay and heal th economic burden.  Sota lo l
has proven to be ef fect ive in  reducing the inc idence of  at r ia l  f ibr i l la t ion af ter  coronary
artery bypass grafting. However, side effects requiring discontinuation of the treatment
are frequently observed.Therefore, the potential benefit of prevention of atrial f ibri l lation




The objectives of the studies described in this thesis were to investigate the rationale
and feasib i l i ty  of  formulat ions of  ant iarrhythmic drugs for  se l f  adminis t rat ion outs ide the
hospital to convert atrial f ibri l lation, to study the efficacy and safety of a selected formula-
t ion and to s tudy pharmacokinet ic  and pharmacodynamic parameters that  are consid-
ered to be important as far as efficacy and safety are concerned and for future research on
this treatment strategy. Furthermore, studies were init iated to investigate the pharmacok-
inet ics and pharmacodynamics of  sota lo l  in  the d i rect  postoperat ive phase of  coronary
artery bypass grafting and to identify risk factors for the development of supraventricular
tachyarrhythmias in  th is  category of  pat ients.
Chapters 1,2 and 3 are in t roductory chapters.  Subsequent ly ,  the thesis  conta ins three
sect ions.  Sect ion I  addresses aspects of  ant iarrhythmic drugs and formulat ions of  these
drugs considered to be important  in  episodic t reatment ,  sect ion l l  focuses on ora l  f lecai -
n ide in  pat ients wi th an episode of  at r ia l  f ibr i l la t ion and sect ion l l l  deals wi th at r ia l  f ibr i l -
la t ion fo l lowing coronary ar tery bypass graf t ing.  F inal ly ,  in  chapter  13 main resul ts  are
discussed and d i rect ions for  fu ture research are o iven.
Antiarrhythmic drugs and formulations in episodic treatment of atrial
f ibri l lation
Due to i ts  s impl ic i ty  of  adminis t rat ion,  ora l  loading could be an opt ion for  se l f  adminis-
tration outside the hospital. In chapter 4 a review of studies in l i terature on oral loading
wi th ant iarrhythmic drugs to restore s inus rhythm in pat ients wi th an episode of  at r ia l
f ibr i l la t ion is  g iven.  In  a l l  s tudies pat ients were hospi ta l ized.The c lass lc  ant iarrhythmic
drugs propafenone and f lecain ide,  appear to be ef fect ive in  convert ing at r ia l  f ibr i l la t ion
and seem to be safe despi te having the potent ia l  o f  t ransforming at r ia l  f ibr i l la t ion in to
atr ia l  f lu t ter  wi th 1:1 at r ioventr icu lar  resoonse.  This adverse ef fect  is  rare and has a lso
been observed in p lacebo t reated pat ients.  Oral  sota lo l ,  amiodarone,  quin id ine,  d igoxin
and verapami l  appear to be less ef fect ive.  Due to the pharmacokinet ics of  f lecain ide,  wi th
low inter indiv idual  var iabi l i ty  of  absorpt ion k inet ics,  no CYP2D6 genotype dependent
format ion of  an act ive metabol i te  and a more rapid d is t r ibut ion to myocardia l  t issue
based on animal  exper iments,  f lecain ide seems to be a bet ter  candidate drug for  episodic
t reatment  of  at r ia l  f ibr i l la t ion than propafenone.  A s ingle ora l  dose of  300 mg f lecain ide
restored sinus rhythm in 59o/o and 680/o f patients at 3 hours.
We stated that  formulat ions of  ant iarrhythmic drugs to be used in episodic t reatment
should be easy to adminis ter  in  the out  c l in ic  set t ing and should g ive a rapid and re-
producib le absorpt ion prof i le ,  wi th h igh,  shor t  last ing peak concentrat ions.  In  chapter  5
the absorpt ion k inet ics of  several  sota lo l  formulat ions are descr ibed.  Sota lo l  is  especia l ly
effective in converting supraventricular tachycardia e.g. AV nodal re-entry tachycardia and
AV rec iprocat ing tachycardia involv ing an accessory AV bypass t ract ,which,  l ike at r ia l  f i -
br i l la t ion,  could a lso be t reated upon the occurrence of  an at tack.  In  an open,  randomized,
crossover s tudy seven heal thy male subjects were g iven an in t ravenous infus ion of  20 mg
of  sota lo l ,  to  assess b ioavai labi l i ty ,  an ora l  so lut ion conta in ing 80 mg of  sota lo l ,  an ora l
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solut ion conta in ing both 80 mg of  sota lo l  and 20 mg of  c isapr ide and an 80 mg sota lo l
tablet  which was taken subl ingual ly .The addi t ion of  c isapr ide to an ora l  so lut ion of  sota lo l
decreased the median time at which maximum serum concentrations were reached from
2.79 h to 1.16 h and increased the geometr ic  mean of  the absorpt ion rate constant  f rom
0.49 h '  to  1.26 h ' .  Compared to the subl ingual ly  adminis tered tablet  wi th a median t ime
of  maximum concentrat ions of  2.12 h and an absorpt ion rate constant  of  0.56 h ' ,  the
sotalol/cisapride oral solution resulted in a much faster absorption of sotalol. Based on the
absorpt ion k inet ics the sota lo l /c isapr ide ora l  so lut ion might  be sui table for  the episodic
treatment of supraventricular tachycardia. However, cisapride has been associated with
the occurrence of  torsade de pointes.  Most  cases were re lated to h igh c isapr ide p lasma
concentrat ions as a resul t  o f  h igh dosages,  renal  insuf f ic iency or  the concomitant  use of
CYP3A4 inhib i tors.  ln  several  countr ies i t  was recommended to avoid the concomitant  use
of  other  QTc pro longing drugs,  such as sota lo l ,  and later  i t  even became contra indicated.
However, in l i terature there are no reported cases of patients with long QTc or torsade de
pointes,  based on the combined use of  sota lo l  and c isapr ide.
Oral  mucosal  drug del ivery has the potent ia l  o f  a rapid onset  of  act ion of  drugs.  Since the
subl ingual  adminis t rat ion of  a convent ional  ora l  sota lo l  tablet  d id not  resul t  in  a rapid
absorpt ion of  sota lo l ,  ex v ivo permeat ion studies through porc ine buccal  mucosa were
performed.  Resul ts  are descr ibed in chapter  6.The t ransport  of  sota lo l  through porc ine
buccal  mucosa f rom an aqueous solut ion d id not  improve by increasing pH f rom 7.4 to
9.0, at which the partit ion coefficient (chloroform/buffer) of sotalol is highest. Sodium gly-
cocholate,  a b i le  sal t  which has proven to enhance the permeat ion of  several  compounds
through buccal  mucosa,  d id not  improve the t ransport  of  sota lo l .  At  pH 7.4,  in  contrast  o
pH 9.0, the addi t ion of  1.0o/o (w/v)  sodium glycocholate even decreased the permeated
amount  of  sota lo l .  F lecain ide base in propylene g lycol  resul ted ex v ivo in  a bet ter  t ransport
of  f lecain ide as compared to an aqueous solut ion of  the more hydrophi l ic  f lecain ide
acetate at pH 5.8.The presence of sodium glycocholate reduced the transport of f lecai-
nide base. Howevet the permeated amount and flux were increased 1 10- and 75-fold by
adding ' l .0olo (w/v) sodium glycocholate to a solution of f lecainide acetate at pH 5.8 with
the permeated amount  of  f lecain ide being 510 pg (1231 nmol) .The h ighest  permeated
amount  obta ined for  sota lo l  was 64 pg (235 nmol) .  F lecain ide,  rather  than sota lo l ,  seems
to be a candidate drug for  the development  of  a buccal  formulat ion.
The two previously described chapters mainly addressed aspects of formulations to be
used in episodic t reatment  of  paroxysmal  at r ia l  f ibr i l la t ion.The rate at  which the at r ia  are
loaded depends both on the rate at  which the drug becomes systemical ly  avai lable and
the rate at  which the drug d is t r ibutes to at r ia l  t issue.  l f  an ant iarrhythmic drug d is t r ibutes
slowly to at r ia l  t issue the impact  of  a more rapid absorpt ion on the rate at  which the
atr ia  are loaded might  be smal l .  The d is t r ibut ion of  f lecain ide to at r ia l  t issue was studied
in patients undergoing coronary artery bypass grafting. The results of this study are
descr ibed in chapter  7.  F lecain ide p lasma levels and r ight  at r ia l  t issue levels were studied
in 13 pat ients.  Six  pat ients received 100 mg of  f lecain ide 2-4 hours pr ior  to  the extracor-
poral circulation. Seven patients received I00 mg of f lecainide two times daily for two
days pr ior  to  coronary ar tery bypass graf t ing and the last  dose was g iven as in  the s ingle
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dose group.  Median rat ios of  t issue and p lasma concentrat ions being 20.1 and 17.8 in  the
single dose and mul t ip le doses group respect ive ly ,  were s imi lar .  F lecain ide at r ia l  t issue
concentrat ions corre lated wel l  wi th f lecain ide p lasma concentrat ions.  l t was concluded
that  f lecain ide d is t r ibutes rapid ly  to at r ia l  t issue.  Both QRS and QTc interval  changes were
not  corre lated wi th e i ther  f lecain ide p lasma or  at r ia l  t issue concentrat ions.These r sul ts
d id not  support  the hypothesis  that  the large pharmacodynamic in ter indiv idual  var iabi l -
i ty  of  f lecain ide occurs due to a h ighly  var iable d isposi t ion of  f lecain ide in  card iac t issue.
Oral loading dosing of f lecainide in patients with an episode of atrial
f ibri l lation
A study was per formed to invest igate ora l  f lecain ide in  convert ing at r ia l  f ibr i l la t ion.The
resul ts  are presented in chapters 8 and 9.  F lecain ide was selected because of  i ts  h igh
ef f icacy in  convert ing at r ia l  f ibr i l la t ion and i ts  rapid d is t r ibut ion to at r ia l  t issue.  Sota lo l
appeared to be ef fect ive in  convert ing supraventr icu lar  tachycardia.  However,  at r ia l  f ibr i l -
la t ion is  more of ten encountered in dai ly  c l in ica l  pract ice.Therefore,  i t  was preferred to
focus on episodic t reatment  of  at r ia l  f ibr i l la t ion instead of  other  supraventr icu lar  tachyar-
rhythmias.  Pat ients were randomly a l located,  s t rat i f ied by the durat ion of  at r ia l  f ibr i l la t ion,
to receive 3 f lecain ide tablets of  ' l  00 mg each or  an ora l  so lut ion conta in ing 300 mg of
f lecain ide and 20 mg of  c isapr ide.The lat ter formulat ion was chosen,  because i t  a l ready
had proven to resul t  in  a favourable absorpt ion prof i le  in  heal thy subjects.  The buccal
adminis t rat ion of  f lecain ide st i l l  had to be invest igated in  man.  Data f rom 54 pat ients
were analysed. ln630/o of  pat ients in  the ora l  so lut ion group and in44o/o f  pat ients in  the
tablets group card iovers ion occurred.  Convers ion rates were not  s tat is t ica l ly  d i f ferent .  In
pat ients wi th at r ia l  f ibr i l la t ion last ing less than 24 hours,  the ora l  so lut ion appeared to
be more effective in restoring sinus rhythm than the tablets. Conversion rates were 88%
and 50% respect ive ly .The ora l  so lut ion reduced the median t ime of  at r ia l  f ibr i l la t ion by
approximately  3 hours,  f rom 3.83 to 0.92 h.  Only minor  adverse ef fects were observed.
Due to the potent ia l  QTc pro longing act iv i ty  of  c isapr ide specia l  a t tent ion was paid to
QTc intervals .  Maximum measured QTc intervals  dur ing the 5 hours 'observat ion per iod
af ter  ingest ion of  f lecain ide were s imi lar  in  both t reatment  groups.A s ingle low dose of  20
mg of  c isapr ide in  the absence of  a CYP 3A4 inhib i tor  d id not  resul t  in  an increase of  QTc
interval  in  our  s tudy pat ients wi thout  severe card iac d isease.
The f lecain ide tablets gave a maximum concentrat ion of  f lecain ide of  0.43 mg/ l  a t  2.37 h
af ter  ingest ion.The ora l  so lut ion resul ted in  a much faster  peak concentrat ion at  1.05 h.
The maximum concentrat ion of  0.60 mg/ l  obta ined wi th the ora l  so lut ion was h igher  as
compared to the tablets.The faster  absorpt ion of  the ora l  so lut ion d id not  resul t  in  a larger
inter indiv idual  var iabi l i ty  of  absorpt ion parameters and parameters descr ib ing the re la-
t ionship between QRS interval  changes and concentrat ions.This was considered import
for safety reasons.The differences in conversion rates of both formulations could not be
expla ined by the observed d i f ferences in  f lecain ide serum concentrat ions reached wi th
the two formulat ions.  Mul t ivar iate analvs is  howed that  a durat ion of  at r ia l  f ibr i l la t ion of
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less than 24 hours (OR:6.34,95o/o Cl :1.70 -  23.73)  and a h igher  absorpt ion rate constant
(OR: 1.20 per  uni t  o f  0.1 h- ' ,  95o/o C|1.01 -  1.44)  increased the probabi l i ty  of  card iovers ion.
It seems that rapid loading of the effect compartment, i.e. the atria, appears to be crit ical
to reach card iovers ion.  In  case of  both formulat ions,  maximum f lecain ide serum concen-
t rat ions and area under the curve could be accurate ly  predicted by l imi ted sampl ing
models us ing 1 or  2 measured concentrat ions.  For  safety reasons i t  has been advised
to star t  episodic t reatment  in  a pat ient  af ter  an in i t ia l  convers ion in  hospi ta l .  Dur ing
the in  hospi ta l  ver i f icat ion the l imi ted sampl ing models are usefu l  to  check whether  the
maximum f lecain ide concentrat ion is  below a,  for  safety reasons,  in i t ia l ly  determined
upper l imi t .These l imi ted sampl ing models can a lso be used in assessing the re lat ionship
between drug exposure and the occurrence of side effects, when data from more patients
become avai lable.
Atrial fibrillation following coronary artery bypass grafting
Dur ing and af ter  coronary ar tery bypass graf t ing pat ients receive mul t ip le drugs and
blood loss can be considerable.  For  pharmacokinet ic  and pharmacodynamic studies in
th is  group of  pat ients a select ive assay for  the determinat ion of  sota lo l  serum concentra-
t ions,  requi r ing a low volume blood sample,  has to be avai lable.  A method wi th a l imi t  o f
detect ion and a l imi t  o f  quant i f icat ion of  0.04 mg/ l  and 0.06 mg/ l  respect ive ly ,  when 0,5 ml
was used,  is  descr ibed in chapter  10.The int ra-assay precis ion and inter-assay precis ion
were 1.1% and 1 1 0/o. There was no interference in the chromatography from drugs which
are commonly used in the immediate postoperat ive phase.
In chapter  11 an observat ional  s tudy to ident i fy  r isk factors for  the occurrence of  su-
praventricular tachyarrhythmias following coronary artery bypass grafting is presented.
Pat ients received sota lo l ,  d i l t iazem or  d igoxin.The data f rom 348 pat ients were analysed.
None of  the t reatments was associated wi th a lower r isk for  the development  of  the ar-
rhythmia.  Supraventr icu lar  tachyarrhythmias,  main ly  at r ia l  f ibr i l la t ion,  occurred in  28o/o f
pat ients.  lndependent  r isk factors were:  a h is tory of  the arrhythmia (OR:25.31 ,95o/o Cl :
5.44 -  117.73) ,  h igher  age (OR per  year  of  age 1.05,95o/o Cl :  1 .02 -  '1 .08) ,  postoperat ive need
for  a temporary pacemaker (OR:2.29,95o/o Cl :1.0 1 -  5.17) ,  preoperat ive t reatment  wi th
digoxin (OR: 5.42, 95o/o Cl:1 .24 - 23.63) and preoperative treatment with an ACE inhibitor
(OR:1.86,95o/oCl :1.03 -  .36) . In the major i ty  of  pat ients who received an ACE inhib i tor
preoperat ive ly ,  th is  agent  was d iscont inued for  at  least  30 hours or  def in i te ly .This suggest
than the renin angiotensin system might  p lay a ro le in  the development  of  the arrhythmia
postoperatively.
In chapter  12 the pharmacokinet ics and pharmacodynamics of  sota lo l  immediate ly
following coronary artery bypass grafting are described. Patients routinely received a
f ixed dose of  40 mg 4 t imes dai ly ,  wi th the f i rs t  dose g iven wi th in 8 hours af ter  the end
of  the operat ion.  Data of  221 pat ients were analysed.  Arrhythmia occurred in  25o/o f
patients and 34o/o f patients developed side effects leading to a temporary or definite
discontinuation of the treatment. Most side effects developed on the first postoperative
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day.  In ter indiv idual  var iabi l i ty  of  sota lo l  serum concentrat ions on the f i rs t  postoperat ive
day was large wi th a coef f ic ient  of  var iance of  144o/o,  which indicates that  the absorpt ion
immediate ly  fo l lowing the operat ion is  var iable.
Concentrat ions of  oat ients whose data were inc luded in a val idat ion data set  could be
accurate ly  predicted.Therefore, the populat ion pharmacokinet ic  model  could be used to
predict  miss ing concentrat ions.  Sota lo l  serum concentrat ions were not  associated wi th
the occurrence of  supraventr icu lar  tachyarrhythmias.  Age wi th an OR of  1.06 (1.02 -  1.09)
per  year  of  age was ident i f ied as independent  r isk factor  for  the development  of  sota lo l
associated side effects.The probabil ity of developing side effects on the second postop-
erat ive day at  a concentrat ion of  1.92 mgl l  was 0.5.  In  pat ients o lder  than 70 years the
probabil ity of side effects was 0.5 at concentrations of 0.56 mg/l and 1 .33 mg/l on the first
and second postoperat ive day respect ive ly .  Consider ing a l l  these aspects,  a sota lo l  dosage
regimen star t ing on the f i rs t  postoperat ive day wi th a low star t ing dose seems to be more
sui table.
Perspectives
Episodic t reatment  of  paroxysmal  at r ia l  f ibr i l la t ion seems an at t ract ive a l ternat ive for
chronic t reatment  wi th ant iarrhythmic drugs.The ef f icacy appears to be dependent  on
the absorpt ion prof i le  of  the pharmaceut ica l  formulat ion.  l t  seems worthwhi le  to inves-
t igate the combinat ion of  f lecain ide and a p-b locker  or  a calc ium channel  antagonist ,
which should prevent  the occurrence of  1:1 AV conduct ion.  In  addi t ion to ef f icacy and
safety,  qual i ty  of  l i fe  scores and heal th care cost  should be end points of  fu ture studies on
eoisodic t reatment .
Fuiure research on prophylact ic  t reatment  wi th ant iarrhythmic drugs should focus on
high risk patients.The balance between benefit and risk of prophylactic treatment with
ant iarrhythmic drugs might  change wi th increasing age.  Despi te a p lethora of  repor ts
on atr ia l  fo l lowing coronary ar tery bypass graf t ing the mechanism is  s t i l l  incomplete ly
understood.  The molecular  and genet ic  basis  has hardly  been studied so far .  From the
observat ional  s tudy the hypothesis  was generated that  the renin angiotensin system
might  be involved in the development  of  the arrhythmias postoperat ive ly .  This  opens
new ouest ions for  fur ther  research.
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